Clinical Trial Update: Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor [Phase 1]

View source ↗

Summary

Phase 1 study evaluating neoadjuvant nivolumab plus ipilimumab for newly diagnosed malignant peripheral nerve sheath tumor. The trial status shows completed enr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Nerve Sheath Tumors | Phase 1 | Status: COMPLETED